NASDAQ:MIRM • US6047491013
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MIRUM PHARMACEUTICALS INC (MIRM).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-27 | TD Cowen | Maintains | Buy -> Buy |
| 2026-03-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-03-04 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2026-02-26 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2026-02-26 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2026-02-26 | TD Cowen | Maintains | Buy -> Buy |
| 2026-02-26 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-02-26 | Stifel | Maintains | Buy -> Buy |
| 2026-02-18 | RBC Capital | Initiate | Outperform |
| 2026-01-30 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2026-01-26 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-12-19 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2025-12-16 | Stifel | Maintains | Buy -> Buy |
| 2025-12-09 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-12-09 | Baird | Maintains | Outperform -> Outperform |
| 2025-12-09 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-11-05 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2025-11-05 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-11-05 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-16 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-09-24 | TD Cowen | Initiate | Buy |
| 2025-09-12 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-08-11 | Stifel | Reiterate | Buy |
| 2025-08-08 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 186.374M 141.86% | 336.888M 80.76% | 521.312M 54.74% | 658M 26.22% | 803M 22.04% | 1.007B 25.40% | 1.301B 29.20% | 1.615B 24.14% | 1.914B 18.51% | 2.177B 13.74% | 2.216B 1.79% | |
| EBITDA YoY % growth | -98.325M 23.17% | -63.977M 34.93% | 2.108M 103.29% | -97.806M -4,739.74% | -95.208M 2.66% | -4.089M 95.70% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -109.154M 16.82% | -87.606M 19.74% | -22.136M 74.73% | -85.572M -286.57% | -1.956M 97.71% | 135.54M 7,029.08% | 430.01M 217.26% | 669.54M 55.70% | 907.98M 35.61% | 1.119B 23.24% | 1.145B 2.32% | |
| Operating Margin | -58.57% | -26.00% | -4.25% | -13.00% | -0.24% | 13.46% | 33.05% | 41.46% | 47.44% | 51.40% | 51.67% | |
| EPS YoY % growth | -3.97 1.17% | -1.85 53.40% | -0.47 74.59% | -1.90 -304.14% | 0.01 100.27% | 1.40 26,742.86% | 4.98 256.26% | 8.21 64.80% | 11.03 34.31% | 13.05 18.27% | 14.38 10.21% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.33 -10.50% | -0.42 -248.50% | -0.46 -1,028.20% | -0.54 -436.22% | -0.47 -43.08% | 0.04 109.76% | 0.14 130.77% | 0.38 170.38% |
| Revenue Q2Q % growth | 152.04M 36.25% | 161.14M 26.10% | 168.53M 26.70% | 180.76M 21.37% | 180.23M 18.54% | 197.57M 22.61% | 212.67M 26.19% | 235.52M 30.29% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -20.89M -37.59% | -24.613M -393.34% | -25.544M -1,081.33% | -22.459M -391.76% | N/A | N/A | N/A | N/A |
All data in USD
17 analysts have analysed MIRM and the average price target is 127.87 USD. This implies a price increase of 32.52% is expected in the next year compared to the current price of 96.49.
MIRUM PHARMACEUTICALS INC (MIRM) will report earnings on 2026-04-30, after the market close.
The consensus EPS estimate for the next earnings of MIRUM PHARMACEUTICALS INC (MIRM) is -0.33 USD and the consensus revenue estimate is 152.04M USD.
The number of analysts covering MIRUM PHARMACEUTICALS INC (MIRM) is 17.